Artiva Biotherapeutics (ARTV) Gains from Investment Securities (2023 - 2026)
Artiva Biotherapeutics (ARTV) reported Gains from Investment Securities of $33000.0 for Q1 2026, down 92.53% year-over-year from $442000.0 in Q1 2025, and up 110.65% quarter-over-quarter from -$310000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Gains from Investment Securities data on file, last reported at $33000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $33000.0, down 92.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$76000.0 (down 127.24% YoY), and the FY2025 annual result was $600000.0, changed N/A from the prior year.
- Gains from Investment Securities advanced to $33000.0 in Q1 2026 per ARTV's latest filing, from -$310000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $1.1 million in Q2 2025 and troughed at -$310000.0 in Q4 2025.
- A 4-year average of $143513.7 and a median of $50358.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities sank 435.56% in 2024, then jumped 1525.81% in 2025.
- A 4-year view of Gains from Investment Securities shows it stood at -$45000.0 in 2023, then slumped by 435.56% to -$241000.0 in 2024, then declined by 28.63% to -$310000.0 in 2025, then soared by 110.65% to $33000.0 in 2026.
- Business Quant data shows ARTV's Gains from Investment Securities at $33000.0 in Q1 2026, -$310000.0 in Q4 2025, and $316300.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Artiva Biotherapeutics | 241.85 Mn | 241.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,000.00 |
| Mar 31, 2026 | 33,000.00 |
| Dec 31, 2025 | -310,000.00 |
| Dec 31, 2025 | -310,000.00 |
| Sep 30, 2025 | 316,300.00 |
| Sep 30, 2025 | 316,300.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 442,000.00 |
| Mar 31, 2025 | 442,000.00 |
| Dec 31, 2024 | -241,000.00 |
| Dec 31, 2024 | -241,000.00 |
| Sep 30, 2024 | 67,716.00 |
| Sep 30, 2024 | 67,716.00 |
| Jun 30, 2024 | 109,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | -31,000.00 |
| Mar 31, 2024 | -31,000.00 |
| Dec 31, 2023 | -45,000.00 |
| Dec 31, 2023 | -45,000.00 |